/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Clare Morgan

Griffith University(AU)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

33

Papers

334

Citations

11

h-index

12

i10-index

Clare Morgan is an academic researcher from Griffith University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Lung Cancer Treatments and Mutations & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 11, co-authored 29 publications.

Research Topics

HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Monoclonal and Polyclonal Antibodies Research Advanced Biosensing Techniques and Applications Spine and Intervertebral Disc Pathology

Papers by this author

works

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

2014 · Breast Cancer Research and Treatment · 49 citations

https://doi.org/10.1007/s10549-014-3239-5

Naomi Elster Mattia Cremona Clare Morgan Sinéad Toomey

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

2018 · BMC Cancer · 21 citations

https://doi.org/10.1186/s12885-018-4035-0

Ozlem Aslan Mattia Cremona Clare Morgan Lydia W.T. Cheung

Additional file 1: Table S1. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

2018 · Figshare · 0 citations

https://doi.org/10.6084/m9.figshare.5876475

Ozlem Aslan Mattia Cremona Clare Morgan Lydia W.T. Cheung

Additional file 2 of Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

2021 · Figshare · 0 citations

https://doi.org/10.6084/m9.figshare.14526521

M. Janusz Mezynski Angela M. Farrelly Mattia Cremona Aoife Carr

Additional file 3: Figure S1. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

2018 · Figshare · 0 citations

https://doi.org/10.6084/m9.figshare.5876508

Ozlem Aslan Mattia Cremona Clare Morgan Lydia W.T. Cheung

Additional file 2: Table S2. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

2018 · Figshare · 0 citations

https://doi.org/10.6084/m9.figshare.5876493

Ozlem Aslan Mattia Cremona Clare Morgan Lydia W.T. Cheung

Research topics

topics

HER2/EGFR in Cancer Research

Lung Cancer Treatments and Mutations

Monoclonal and Polyclonal Antibodies Research

Advanced Biosensing Techniques and Applications

Spine and Intervertebral Disc Pathology

Chat about Author

Papers

Chat

Click to start Chat